Shilpa Medicare Limited

Shilpa Medicare Ltd Submits SEBI Compliance Certificate for Q3 FY26

Shilpa Medicare Limited submitted a SEBI compliance certificate for the quarter ended December 31, 2025. The certificate, received from Registrar and Share Transfer Agent Kfin Technologies Limited, confirms the dematerialization and rematerialization of securities as per regulations.

Shilpa Medicare Receives Ex-Parte Injunction on Ruxolitinib Product

Shilpa Medicare and its subsidiaries received an ex-parte injunction from the Delhi High Court restraining the manufacturing and sale of Ruxolitinib-based products due to alleged patent infringement. The company states there is no financial impact and operations continue as usual.

Shilpa Medicare: Trading Window Closed Jan 1, 2026, for Q3 FY26 Results

Shilpa Medicare's trading window will be closed from January 1, 2026. This closure is in anticipation of the un-audited financial results for the quarter ending December 31, 2025. The window will reopen 48 hours after the results are declared.

Shilpa Medicare Receives European Authorization for Rotigotine Transdermal Patch

Shilpa Medicare has received initial European authorization for its Rotigotine transdermal patch, a generic of Neupro®. The European market for Rotigotine is estimated at USD 222 million (~₹1,847.8 crore). A launch is targeted for FY27. This is the company's first transdermal patch to receive European marketing authorization.

Shilpa Medicare Approves Unaudited Results for Quarter Ended September 30, 2025

Shilpa Medicare board approves unaudited financial results for quarter ended September 30, 2025. Standalone revenue from operations for the quarter ended September 30, 2025, was ₹13,493.28 lakhs.

USFDA Inspection Completed at Shilpa Medicare Unit IV, Jadcherla

USFDA inspection of Shilpa Medicare's Unit IV in Jadcherla, Telangana, concluded on November 21, 2025, with eight observations, none repeated. The facility supports US, Europe, and other markets.

Shilpa Medicare Announces Transcript of Q2 FY26 Conference Call

Shilpa Medicare releases Q2 FY26 concall transcript, highlighting record EBITDA of ₹110 cr, product launches, and capex plans.

Shilpa Medicare uploads Q2-FY26 Earnings Conference Call recording

Shilpa Medicare uploaded the audio recording of its Q2-FY26 earnings conference call, held on November 17, 2025, to its website for investor access.

Shilpa Medicare Launches NODUCA™ for MAFLD Treatment in India

Shilpa Medicare launches NODUCA™ in India, a novel therapy for MAFLD, following regulatory approval. Clinical trials showed significant efficacy and safety. The company aims for global expansion.

Shilpa Medicare Investor Presentation for Quarter Ended 30 September 2025

Shilpa Medicare releases investor presentation for quarter ended September 30, 2025, reporting revenue growth of 8% YoY for H1 FY26 and EBITDA growth of 20% YoY. Concall on November 17, 2025.

Shilpa Medicare Approves Unaudited Standalone & Consolidated Financial Results

Shilpa Medicare Limited's Board approved unaudited financial results for the quarter and half-year ended September 30, 2025. The meeting was held on November 13, 2025.

Shilpa Medicare Approves Unaudited Standalone & Consolidated Results

Shilpa Medicare's board approved unaudited standalone and consolidated financial results for the quarter and half-year ended September 30, 2025, at its meeting on November 13, 2025.

Shilpa Medicare Board Approves Q2 & H1 FY26 Unaudited Standalone & Consolidated Financial Results

Shilpa Medicare's board approved Q2 and H1 FY26 unaudited standalone and consolidated financial results on November 13, 2025, for the period ended September 30, 2025.

Shilpa Medicare: Postal Ballot Results Published in Newspapers

Shilpa Medicare announced the results of its postal ballot, with shareholders approving the reclassification of Mr. Suraj Kumar Inani and Ms. Priya Inani from 'Promoter group' to 'Public' category.

Shilpa Medicare announces postal ballot results for reclassification of two promoter group members to public

Shilpa Medicare announced postal ballot results for reclassification of Mr. Suraj Kumar Inani and Ms. Priya Inani from promoter to public category, passed with 97.158% votes in favour.

Shilpa Medicare Announces Positive Phase 3 Results for OERIS™

Shilpa Medicare announced positive Phase 3 results for OERIS™, a novel injection for Chemotherapy-Induced Nausea and Vomiting, demonstrating superior convenience and efficacy. Regulatory submission is in progress.

Shilpa Pharma Lifesciences Awarded Gold Medal by EcoVadis for Sustainability

Shilpa Pharma Lifesciences, a subsidiary of Shilpa Medicare, receives the EcoVadis Gold Medal for sustainability, scoring 82/100 and ranking in the 98th percentile globally.

Shilpa Medicare Announces Q2 FY26 Earnings Conference Call on November 17, 2025

Shilpa Medicare to announce Q2 FY26 results on Nov 13, 2025, followed by an earnings call on Nov 17, 2025, at 11:00 hrs. Call details provided.

Shilpa Medicare Sells 31% Stake in Sravathi for ₹49.6 Crore

Shilpa Medicare sells 31% stake in Sravathi Advance Process Technologies to Ash Ingredients Inc. & Varcatalyst LLP for ₹49.6 crore, altering shareholding structure and board composition.

Promoters of Shilpa Medicare enter into an Inter-se Agreement

Shilpa Medicare's promoters entered an inter-se agreement on October 16, 2025, concerning security transfers, rights, and obligations, without altering company control or shareholding.

Promoters enter into inter-se agreement on 16 Oct 2025

Promoters of Shilpa Medicare entered into an inter-se agreement on October 16, 2025, outlining terms for securities transfer, rights, and obligations among the promoter group, holding 40.14% of shares.

Compliance Certificate under SEBI Regulations for Quarter Ended 30 Sep 2025

Shilpa Medicare Limited submits compliance certificate under SEBI Regulations for quarter ended 30 September 2025 from Kfin Technologies Limited.

Shilpa Medicare announces Postal Ballot for reclassification of two promoters to public category

Shilpa Medicare announced a postal ballot for reclassifying two promoters to the public category. E-voting is from Oct 9 to Nov 8, 2025. Results expected by Nov 10, 2025.

Shilpa Medicare Announces Postal Ballot for Reclassification of Promoter Group to Public

Shilpa Medicare announced a postal ballot for reclassifying Mr. Suraj Kumar Inani and Ms. Priya Inani from promoter to public category, with e-voting from Oct 9 to Nov 8, 2025.

Shilpa Medicare Allots Bonus Equity Shares

Shilpa Medicare allots 9,77,90,908 bonus equity shares in the ratio of 1:1, increasing the paid-up share capital to ₹19,55,81,816. The record date was October 03, 2025.

Shilpa Medicare receives in-principle approval for 1:1 bonus issue from NSE

Shilpa Medicare receives approval for reclassification of 4.09% promoter shareholding to public category

Shilpa Medicare receives in-principle approval for 1:1 bonus share issue

Shilpa Medicare receives regulatory approval for reclassification of 4.09% promoter group shares to public

Shilpa Medicare receives 'Crisil ESG 51' score from independent CRISIL ESG Ratings

Shilpa Medicare: Outcome of 38th AGM held on 23 September 2025

Dr. Kamal Kishore Sharma completes tenure as Independent Director

Shilpa Medicare Limited: Proceedings of 38th Annual General Meeting

Shilpa Medicare receives initial European authorization for Rivaroxaban Orodispersible Films

Shilpa Medicare Announces 38th AGM, Final Dividend, and E-Voting Details

Shilpa Medicare Ltd. Announces 38th AGM on September 23, 2025, and FY25 Annual Report Availability

Shilpa Medicare's Subsidiary Partners with Saudi PPI for New Pharma Manufacturing JV in Saudi Arabia

Shilpa Medicare informs shareholders about TDS on final dividend

Shilpa Medicare to hold 38th AGM on September 23, 2025 via VC/OAVM

Shilpa Medicare Files FY25 BRSR, Details Strong ESG Commitments & Performance

Shilpa Medicare revises record date for 1:1 bonus share issue to 03 October 2025

Shilpa Medicare Q1 FY26 Earnings: Highest Ever Quarterly EBITDA

Shilpa Medicare to host Q1 FY2025-26 earnings conference call on August 13, 2025

Shilpa Medicare invests US$ 2 million in Alveolus Bio